eBook - ePub
Biotechnology and Biopharmaceuticals
Transforming Proteins and Genes into Drugs
This is a test
Partager le livre
- English
- ePUB (adapté aux mobiles)
- Disponible sur iOS et Android
eBook - ePub
Biotechnology and Biopharmaceuticals
Transforming Proteins and Genes into Drugs
DĂ©tails du livre
Aperçu du livre
Table des matiĂšres
Citations
Ă propos de ce livre
Biotechnology and Biopharmaceuticals: Transforming Proteins and Genes into Drugs, Second Edition addresses the pivotal issues relating to translational science, including preclinical and clinical drug development, regulatory science, pharmaco-economics and cost-effectiveness considerations. The new edition also provides an update on new proteins and genetic medicines, the translational and integrated sciences that continue to fuel the innovations in medicine, as well as the new areas of therapeutic development including cancer vaccines, stem cell therapeutics, and cell-based therapies.
Foire aux questions
Comment puis-je résilier mon abonnement ?
Il vous suffit de vous rendre dans la section compte dans paramĂštres et de cliquer sur « RĂ©silier lâabonnement ». Câest aussi simple que cela ! Une fois que vous aurez rĂ©siliĂ© votre abonnement, il restera actif pour le reste de la pĂ©riode pour laquelle vous avez payĂ©. DĂ©couvrez-en plus ici.
Puis-je / comment puis-je télécharger des livres ?
Pour le moment, tous nos livres en format ePub adaptĂ©s aux mobiles peuvent ĂȘtre tĂ©lĂ©chargĂ©s via lâapplication. La plupart de nos PDF sont Ă©galement disponibles en tĂ©lĂ©chargement et les autres seront tĂ©lĂ©chargeables trĂšs prochainement. DĂ©couvrez-en plus ici.
Quelle est la différence entre les formules tarifaires ?
Les deux abonnements vous donnent un accĂšs complet Ă la bibliothĂšque et Ă toutes les fonctionnalitĂ©s de Perlego. Les seules diffĂ©rences sont les tarifs ainsi que la pĂ©riode dâabonnement : avec lâabonnement annuel, vous Ă©conomiserez environ 30 % par rapport Ă 12 mois dâabonnement mensuel.
Quâest-ce que Perlego ?
Nous sommes un service dâabonnement Ă des ouvrages universitaires en ligne, oĂč vous pouvez accĂ©der Ă toute une bibliothĂšque pour un prix infĂ©rieur Ă celui dâun seul livre par mois. Avec plus dâun million de livres sur plus de 1 000 sujets, nous avons ce quâil vous faut ! DĂ©couvrez-en plus ici.
Prenez-vous en charge la synthÚse vocale ?
Recherchez le symbole Ăcouter sur votre prochain livre pour voir si vous pouvez lâĂ©couter. Lâoutil Ăcouter lit le texte Ă haute voix pour vous, en surlignant le passage qui est en cours de lecture. Vous pouvez le mettre sur pause, lâaccĂ©lĂ©rer ou le ralentir. DĂ©couvrez-en plus ici.
Est-ce que Biotechnology and Biopharmaceuticals est un PDF/ePUB en ligne ?
Oui, vous pouvez accĂ©der Ă Biotechnology and Biopharmaceuticals par en format PDF et/ou ePUB ainsi quâĂ dâautres livres populaires dans Biological Sciences et Biotechnology. Nous disposons de plus dâun million dâouvrages Ă dĂ©couvrir dans notre catalogue.
Informations
Part I
TRANSFORMING PROTEINS AND GENES INTO DRUGS
The Science and the Art
Transformation of biotechnology and scientific discoveries into therapeutic products is a science and could be considered as an art. Biopharmaceutical products are mainly derived from peptides, nucleic acid polymers, and proteins. They are often referred to as biologics, biomolecules, biotherapeutics, macroÂmolecules, and protein therapeutics. In this book, we will use these terms interchangeably with the term biopharmaceuticals. The following eight chapters introÂduce the process of leveraging a series of discoveries in biological macroÂmolecules, including identification of their structures and elucidating their physiological roles for application as therapeutic agents. The path to prove a therapeutic molecule is safe and effective for patients is often complex and depends on science and more. With the advancement of recombinant DNA technology and the rapid growth in automation efficiency and computing power, many more drug targets are available to produce (recombinant or synthetic) drugs or pharmaceuticals. The discussions that follow document the knowledge and the experience gained from transforming biological macromolecules into drugs. The series of chapters highlight some of the key differences between the discovery and development of small-molecule drugs and high-molecular-weight biopharmaceuticals. The growing appreciation of the pivotal roles that public and private organizations play in supporting the enabling technologies through financial resources and leveraging all resources for drug development is an evolving art. Transformation of biomolecules into biopharmaceutiÂcals includes buildÂing capacity, evaluating therapeutic potential, and testing whether a molecule clears a defined set of tests in a test tube, in animals, and eventually in humans. The therapeutic molecules that clear the safety and efficacy evaluations and become endorsed by the US Food and Drug Administration are approved for human use. How the drug industry develops a price for a new therapy is an art. These integrated topics have proved to be increasingly imporÂtant for decision makers, pharmaceutical scientists, and physicians in their practice.
1
INTRODUCTION TO BIOPHARMACEUTICALS
1.1. Background and Significance
1.2. Translation of Biotechnology for Developing Biopharmaceuticals
1.3. Historical Perspective of Pharmaceutical Biotechnology
1.4. Distinctions between Chemical Drugs Versus Biopharmaceuticals
1.5. Summary
Biopharmaceuticals, otherwise known as the application of biomolecules as therapeutic products, have benefited from advances in the study of biology and biological interactions of simple and complex organisms including prokaryotes, eukaryotes, and mammalian systems. Basic discoveries and a greater understanding of Âbiochemistry and biophysics have shed light on the abnormalities of the highly coordinated biological systems in humans that are related to disease symptoms. These discoveries have allowed for innovations to be made in the design and development of biopharmaceuticals for treating a wide range of human diseases. While biotechnology today is synonymous with advanced technologies, the technology of using biological molecules as therapeutics has been in existence since the 1800 s. Ever since elucidating that the human body is composed of specialized cells and proteins, exponential advances have provided enabling technologies that consistently produce high-quality proteins, antibodies, and peptides for pharmaceutical applications. Continued refinement and optimization of the production of recombinant macromoleculesâenzymes, growth hormones, vaccines, and monoclonal antibodiesâhave fueled, and will continue to fuel, the growth and influence in overall drug development. When this text was first published in 2003, only a handful of biopharmaceuticals reached US $1 billion in annual sales. At the time of writing this second edition, the top-selling biopharmaceuticals reached US $7.3 billion, and the top 25 biopharmaceutical products generated US $74.7 billion in 2010. With over 200 biopharmaceutical products on the market, these achievements were possible because of the outstanding contribution of scientists and clinicians and their collective efforts to collaborate and integrate innovations into novel therapeutic products. This chapter defines the differences between small-molecule or traditional drugs and biologics or biotherapeuticsâproteins, peptides, and biological materialsâthat are much larger molecules. A small change at the atomic level for a small-molecule drug typically leads to a new drug with a unique set of therapeutic and side effects, whereas a modification of amino acids (with multiple atomic modifications) on protein-based biotherapeutics, such as insulin and hepatitis B vaccine, retains a very similar therapeutic profile and clinical application. This chapter introduces in an easy-to-read level the growth in new biopharmaceuticals reaching the market, their therapeutic importance, and their overall contribution to health care. It is intended for students, health professionals, legislators, decision makers, and pharmaceutical researchers who want to learn about the science and business of biotechnology and its role in transforming biological discoveries into therapeutic products.
1.1. BACKGROUND AND SIGNIFICANCE
For most people, biotechnology is synonymous with âhigh-technology or advanced technologyâ. However, the idea to use technology or products derived from biological molecules and processes for disease treatment is not new. Even before the discovery that the human body is composed of cells and proteins, humans were constantly being challenged by invading pathogenic microbes and other deadly infections. These real and perceived battlefields of disease necessitated innovations for developing curative medicinesâbiologically active therapeutic products now recognized as bioÂpharmaceuticals. While biotechnology today is seen as the cutting edge of life sciences, the use of biological molecules as therapeutic agents or biologics has existed since the 1800 s. In fact, the word biotechnology can be traced back to the 1919 writing of Kark Erely in his 84-page publication entitled, âBiotechnologie der Fleisch-, Fett- und Milcherzeugung im landwirtschafttichen Gross-betriebâ (Bud 1989). The coining of the term biotechnologie or âbiotechnologyâ by Erely was likely intended to describe the interaction of biology with technology, thus essentially implying inclusion of all biological and related technologies in product ÂtransÂformation. Today, the therapeutic products of ÂbioÂtechnologies, which are referred to as biologics or biopharmaceuticals, are central in providing hope and in making advances for treating human diseases ranging from infections, diabetes, and immune disorders to Âcancers. Biopharmaceuticals are derived from peptides and proteins, which are often referred to as Âbiologics, biomolecules, biotherapeutics, macromolecules, and Âprotein therapeutics. In this book, we will use these terms interchangeably when referring to bioÂpharmaceuticals.
The transformation of basic biological processes and endogenous proteins to biopharmaceuticals that treat disease and provide cures requires integration of scientific discovery and ingenuity into product development. The synthesis of biopharmaceuticalsâproteins, peptides, and genetic materialsâ at a quality and quantity suitable for therapeutic use is a recent achievement. Some of the milestones and innovations pivotal to therapeutic achievements are highlighted in Figure 1.1. Clearly, basic knowledge about the DNA and the genetic code, different cells that make up Âtissues and organs, and protein synthesis and cellular mechanisms provided the foundation for exponential growth in biotechnology. Some of the significant Âbiotechnology milestones and innovations are (1) recombinant DNA technology (procedures that join together, or recombine, DNA segments) to proÂduce human protein in foreign host cells (Cohen, Chang et al. 1973); (2) cell and fermentation technologies for large-scale protein production (Goeddel 1990); and (3) monoclonal antibody technologies (Kohler and Milstein 1975) that provide antibody Âtherapeutics for treating immune or other disorders and cancers. These technological milestones have enabled transformation of biomolecules into Âbiotherapeutics, which now impact health every day. Without transformational biotechnoÂlogies, the health impacts of biotherapeutics such as Âproteins, antibodies, and enzymes (some of which are still available as tissue- or plasma-extracted products), would have been realized much later. Figure 1.1 also highlights the integration and potential impact due to the ever-expanding knowledge of biological processes and bioengineering. These scientific and engineering achieveÂments have allowed development and use of protein- and antibody-based therapies that require large doses (typically in milligrams or higher amounts) to impact patient health.
Translating biotechnology innovations into theraÂpeutic products requires investment by biopharmaceutical companies that focus on preclinical and clinical product development. While there are many entrepreneurial biotechnology start-up companies working on early-stage therapeutics, a majority of pioneering biotechnology companies, such as Genentech, Chiron, Cetus, and Immunex, that had success in developing therapeutic products, are eventually acquired by large pharmaceutical companies. This strategic acquisition of biotechnology companies has accelerated over the past 10 years. As a result, as shown in Table 1.1, Amgen is the only independent biotechnology company on the list. The other two companies, Genzyme and Biogen Idec, are part of or in the process of being integrated into large pharmaceutical companies. Table 1.1 also compares biotechnology and integrated biopharmaceutical companies and their 2010 revenue, market share, productivity as measured by revenue per employee, and investment in research and development (R&D). Although the total employee numbers are still relatively small, all of the listed biotechnology companies have grown to realize multi-billion dollar annual revenues, and their productivity is comparable to that of integrated biopharmaceutical companies ($632,000 vs. $506,000 per employee, respectively; Table 1.1). Biotechnology companies spend more than 20% (mean = 26%) of their revenue on R&D. This is well above the 11%â24% (mean = 16%) of revenue inve...